Neuromuscular Disorders
We work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.
Overview
We study diseases that affect neuromuscular transmission, with the major focus on mutations of muscle acetylcholine receptors (AChR) and of proteins that govern synaptic structure.
Research
The neuromuscular synapse is both well understood and accessible for study. Functional analysis of mutations at the molecular level can be directly correlated with measurements of defective synaptic transmission in vivo and with the clinical features of the patients.
The work ranges from the studies of single channels, through to animal models of disease, to phenotypic characterisation of patients. It provides translational research of bedside to bed and back, with the bench research generating data directly relevant to patient treatment regimes. Moreover, a detailed knowledge of inherited dysfunction of neuromuscular transmission forms a paradigm for investigation of other neurological syndromes that may result from defective synaptic transmission in the CNS.
Research projects
- Developing new diagnostic tools for congenital myasthenia
- Using a combination of biochemistry, molecular biology, electrophysiology and advanced microscopy to study the molecular mechanisms underlying disease
- Testing novel therapies for inherited disorders of neuromuscular transmission using transgenic models
Congenital Myasthenia Service
The Congenital Myasthenia Service provides a nationally commissioned specialised service for the diagnosis and management of children and adults in whom a congenital myasthenic syndrome is suspected.
Latest publications
Gut microbiota restricts intestinal lipid uptake via modulation of bile phosphatidylcholine metabolism in mice.
Journal article
Brunner S. et al, (2026), Nat Microbiol, 11, 2349 - 2364
The Thrombopoietin Receptor S264F Mutant Drives MPN with Marrow Fibrosis Through a Dual Mechanism
Journal article
MEAD A., (2026), HemaSphere
Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity.
Journal article
Anselmi G. et al, (2026), Cell Rep, 45
Nucleophagy as an emerging therapeutic vulnerability in cancer.
Journal article
Tribble S. and Ramadan K., (2026), Autophagy, 1 - 3